IMpower133: exploratory analysis of maintenance therapy in patients with extensive-stage small-cell lung cancer
In the I/III IMpower133 study, patients with extensive-stage small cell lung cancer received carboplatin + etoposide in combination with atezolizumab or placebo, followed by maintenance therapy with atezolizumab or placebo. This exploratory analysis examined the benefit of atezolizumab vs placebo maintenance treatment in patients who reached the maintenance phase of the study.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.